Lenvatinib, 98%

Name: Lenvatinib, 98% | 417716-92-8
Brand: J&K Chemical
SKU: JK913333_1_G
Price: 61.64 USD
Availability: OutOfStock

Cat. No JK913333_1_G

Vendor: J&K Chemical

Product Information

Product Name

Lenvatinib, 98%

Brand Name

J&K

Product Number

913333

CAS

417716-92-8

Molecular Formula

C21H19ClN4O4

Molecular Weight

426.85

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

9823820

IUPAC Name

4-3-chloro-4-(cyclopropylcarbamoylamino)phenoxy-7-methoxyquinoline-6-carboxamide

InChI Key

WOSKHXYHFSIKNG-UHFFFAOYSA-N

SMILES

COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl

Properties

Melting Point

226

Safety Information

GHS Symbols

Signal Word

Warning

Hazard Statement

H361

Precautionary Statement

P280

P405

P203

P318

Storage Condition

Freezer -20℃

References Data Source From Pubchem

[Clinician and medical scientists in internal medicine: gastroenterology]

Publication Name: Innere Medizin (Heidelberg, Germany)

Publication Date: 2026-04

DOI: 10.1007/s00108-026-02084-7

Physical Activity and Hepatocellular Carcinoma Outcomes: a Narrative Review of Pre-clinical, Observational, and Interventional Evidence

Publication Name: Journal of Gastrointestinal Cancer

Publication Date: 2026-03-05

DOI: 10.1007/s12029-026-01420-2

Perioperative approaches for patients with biliary tract cancer

Publication Name: Nature reviews. Clinical oncology

Publication Date: 2026-03-03

DOI: 10.1038/s41571-026-01130-5

Reply to “Performance of risk models in predicting outcomes of atezolizumab and bevacizumab therapy”

Publication Name: Journal of Gastroenterology

Publication Date: 2026-03-03

DOI: 10.1007/s00535-026-02381-w

Cabozantinib

Publication Name: Reactions Weekly

Publication Date: 2026-02-28

DOI: 10.1007/s40278-026-92759-1

Lenvatinib, 98%

Product Information

General Information

Properties

Safety Information

References Data Source From Pubchem

[Clinician and medical scientists in internal medicine: gastroenterology]

Physical Activity and Hepatocellular Carcinoma Outcomes: a Narrative Review of Pre-clinical, Observational, and Interventional Evidence

Perioperative approaches for patients with biliary tract cancer

Reply to “Performance of risk models in predicting outcomes of atezolizumab and bevacizumab therapy”

Cabozantinib

Lenvatinib, 98%

N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-3-methoxy-L-phenylalanine

2-Ethynyl-1,3,5-trimethylbenzene, 97%

Tris-acetic acid electrophoresis buffer (50×TAE)

[S(R)]-N-[(1S)-1-[2-(Diadamantanphosphino)phenyl]ethyl]-N,2-dimethyl-2-propanesulfinamide, 95%

Mycophenolate Mofetil EP Impurity H

3-(4-Bromo-2-fluoro-3-methoxyphenyl)-3-oxo-propionic acid ethyl ester

Isochroman-1-carboxylic acid

Mycophenolate Mofetil

About Us

Popular Searches

Contact

#title#

Features
Availability:
Price
Options
Actions

Lenvatinib, 98%

Product Information

General Information

Properties

Safety Information

References Data Source From Pubchem

[Clinician and medical scientists in internal medicine: gastroenterology]

Physical Activity and Hepatocellular Carcinoma Outcomes: a Narrative Review of Pre-clinical, Observational, and Interventional Evidence

Perioperative approaches for patients with biliary tract cancer

Reply to “Performance of risk models in predicting outcomes of atezolizumab and bevacizumab therapy”

Cabozantinib

Lenvatinib, 98%

Related Product

N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-3-methoxy-L-phenylalanine

2-Ethynyl-1,3,5-trimethylbenzene, 97%

Tris-acetic acid electrophoresis buffer (50×TAE)

[S(R)]-N-[(1S)-1-[2-(Diadamantanphosphino)phenyl]ethyl]-N,2-dimethyl-2-propanesulfinamide, 95%

Mycophenolate Mofetil EP Impurity H

3-(4-Bromo-2-fluoro-3-methoxyphenyl)-3-oxo-propionic acid ethyl ester

Isochroman-1-carboxylic acid

Mycophenolate Mofetil

#title#

Login

Register